Washington, D.C. (February 25, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) Executive Vice President of Scientific and Regulatory Affairs Dr. Bill Chin issued the following statement today in support of legislation to prevent sequestration of prescription drug user fees:
“PhRMA strongly supports the FDA Safety Over Sequestration Act, which would exempt future Food and Drug Administration’s (FDA) user fees from sequestration. We commend Representatives Leonard Lance (R-NJ) and Anna Eshoo (D-CA) for their continued leadership on this critical issue.
“PhRMA remains deeply concerned about the impact of potential sequestration in the future on the FDA’s ability to fulfill its critical public health mission by fostering timely patient access to safe and effective new medicines and advancing regulatory science.
“Prescription drug user fees cannot, by law, be used for any purpose other than to support FDA’s human drug review program. Their sequestration does not decrease the nation’s deficit, but only serves to exacerbate the severe budgetary constraints of a historically underfunded agency. This is detrimental to patients, regulatory science and public health.”
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $550 billion in the search for new treatments and cures, including an estimated $51.1 billion in 2013 alone.
Connect with PhRMA
For information on how innovative medicines save lives, please visit: